Literature DB >> 22135721

β-catenin expression in benign and malignant pleural disorders.

Waseem Anani1, Richard Bruggeman, Dani S Zander.   

Abstract

Benign and malignant pleural processes display a large and overlapping spectrum of morphological appearances, and can be difficult to distinguish, histologically, from each other. β-catenin, a participant in the wingless-type (Wnt) transduction pathway, is involved in the pathogenesis of malignant mesothelioma and has received limited evaluation for its ability to serve as a diagnostic aid for distinguishing between individual pleural disorders. We performed immunohistochemistry for β-catenin on 10 pleural malignant mesotheliomas, 10 examples of mesothelial hyperplasia and 18 cases of organizing pleuritis. Although differences were noted in staining intensity between the mesothelioma and mesothelial hyperplasia groups, extensiveness and cellular location were similar. Staining intensity (mean +/- s.d.) in mesotheliomas (2.00 +/- 0.67) was significantly less intense than in mesothelial hyperplasia cases (3.00 +/- 0.00) (p=0.0005). Stromal cell staining was cytoplasmic in all cases, and endothelial cell staining was membranous, submembranous and cytoplasmic. Nuclear expression of β-catenin was not observed in any of the cases studied. This lack of nuclear staining in the stromal cells of organizing pleuritis differs markedly from the previously reported high frequencies of nuclear β-catenin expression in other pleural spindle cell proliferations (desmoid tumors and solitary fibrous tumors). In summary, the current study adds to previous work indicating a role for β-catenin in the genesis of pleural conditions including organizing pleuritis, mesothelial hyperplasia and malignant mesothelioma. Although IHC for β-catenin does not appear to be conclusive for separating benign from malignant mesothelial proliferations, it may be valuable for assisting in the differential diagnosis of mesothelial and spindle cell proliferations in the pleura.

Entities:  

Keywords:  Wnt; mesothelial hyperplasia; mesothelioma; pleura; β-catenin

Mesh:

Substances:

Year:  2011        PMID: 22135721      PMCID: PMC3225785     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  24 in total

Review 1.  The many ways of Wnt in cancer.

Authors:  Paul Polakis
Journal:  Curr Opin Genet Dev       Date:  2007-02       Impact factor: 5.578

2.  Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma.

Authors:  Yasufumi Kato; Koji Tsuta; Kunihiko Seki; Akiko Miyagi Maeshima; Shunichi Watanabe; Kenji Suzuki; Hisao Asamura; Ryosuke Tsuchiya; Yoshihiro Matsuno
Journal:  Mod Pathol       Date:  2006-12-22       Impact factor: 7.842

3.  The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.

Authors:  Farnaz Hasteh; Grace Y Lin; Noel Weidner; Claire W Michael
Journal:  Cancer Cytopathol       Date:  2010-04-25       Impact factor: 5.284

4.  The expression pattern of beta-catenin in mesothelial proliferative lesions and its diagnostic utilities.

Authors:  Yiran Dai; Carlos W M Bedrossian; Claire W Michael
Journal:  Diagn Cytopathol       Date:  2005-11       Impact factor: 1.582

5.  Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium.

Authors:  Ayuko Sato; Ikuko Torii; Yoshihiro Okamura; Tadashi Yamamoto; Takashi Nishigami; Tatsuki R Kataoka; Misa Song; Seiki Hasegawa; Takashi Nakano; Toshiaki Kamei; Tohru Tsujimura
Journal:  Mod Pathol       Date:  2010-07-23       Impact factor: 7.842

6.  Cell proliferation rate and telomerase activity in the differential diagnosis between benign and malignant mesothelial proliferations.

Authors:  Caglar Cakir; Mine G Gulluoglu; Dilek Yilmazbayhan
Journal:  Pathology       Date:  2006-02       Impact factor: 5.306

7.  Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.

Authors:  Krisztina Z Hanley; Michael S Facik; Patricia A Bourne; Qi Yang; Betsy O Spaulding; Thomas A Bonfiglio; Haodong Xu
Journal:  Cancer       Date:  2008-02-25       Impact factor: 6.860

8.  Tenascin-X is a novel diagnostic marker of malignant mesothelioma.

Authors:  Yuan Yuan; Dag André Nymoen; Helene Tuft Stavnes; Anne Katrine Rosnes; Ola Bjørang; Chuanyue Wu; Jahn M Nesland; Ben Davidson
Journal:  Am J Surg Pathol       Date:  2009-11       Impact factor: 6.394

9.  IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.

Authors:  Katsuhide Ikeda; Genshu Tate; Takao Suzuki; Takashi Kitamura; Toshiyuki Mitsuya
Journal:  Hum Pathol       Date:  2010-01-13       Impact factor: 3.466

Review 10.  Update on the molecular biology of malignant mesothelioma.

Authors:  Amie Y Lee; Dan J Raz; Biao He; David M Jablons
Journal:  Cancer       Date:  2007-04-15       Impact factor: 6.860

View more
  2 in total

1.  In pulmonary sclerosing hemangioma expression of β-catenin, Axin, and C-myc differs between the two cell types.

Authors:  Xu-Yong Lin; Di Zhang; Yong Zhang; Chui-Feng Fan; Shun-Dong Dai; En-Hua Wang
Journal:  Virchows Arch       Date:  2012-05-22       Impact factor: 4.064

Review 2.  Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review.

Authors:  Rossella Bruno; Greta Alì; Gabriella Fontanini
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.